Amgen Reports Results of Aimovig (erenumab-aooe) in P-lV Study for the Treatment of Episodic and Chronic Migraine
Shots:
- The P-IV HER-MES study evaluates the tolerability & efficacy of Aimovig (70/140mg) vs topiramate in 777 patients with episodic or chronic migraine (=4 migraine days/month) prior to not being treated with migraine prevention treatment or previously failed up to 3 previous therapies. The study was conducted in collaboration with Novartis at 82 study sites in Germany
- The results showed a lower discontinuation rate due to AEs (10.6% vs 38.9%). Additionally, a greater proportion of patients achieved at least a 50% reduction from baseline in their MMDs (55.4% vs 31.2%)
- Aimovig is the 1st FDA-approved migraine preventive treatment that targets CGRP receptors associated with migraine
Ref: PR Newswire | Image: Amgen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com